Skye Bioscience (SKYE) Prepaid Assets (2013 - 2026)
Skye Bioscience (SKYE) posted quarterly Prepaid Assets of $234806.0 for Q1 2026, down 59.19% year-over-year from $575382.0 in Q1 2025, and down 72.44% quarter-over-quarter from $852036.0 in Q4 2025.
Skye Bioscience (SKYE) Prepaid Assets (2013 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Prepaid Assets for 14 consecutive years, with $234806.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Prepaid Assets fell 59.19% year-over-year to $234806.0; the TTM figure through Mar 2026 stood at $234806.0 (down 59.19% YoY), while the FY2025 annual figure was $852036.0, up 321.88% from the prior year.
- Prepaid Assets retreated to $234806.0 in Q1 2026 per SKYE's latest filing, from $852036.0 in the prior quarter.
- Across five years, Prepaid Assets topped out at $2.7 million in Q3 2024 and bottomed at $143859.0 in Q3 2022.
- Historically, Prepaid Assets has averaged $935861.9 across 5 years, with a median of $871428.0 in 2022.
- Annual changes were most pronounced in 2022 — Prepaid Assets jumped 1272.97% — and 2024, when it slumped 81.97%.
- Skye Bioscience's Prepaid Assets stood at $780807.0 in 2022, then surged by 43.43% to $1.1 million in 2023, then sank by 81.97% to $201962.0 in 2024, then soared by 321.88% to $852036.0 in 2025, then slumped by 72.44% to $234806.0 in 2026.
- Business Quant data shows SKYE's Prepaid Assets at $234806.0 in Q1 2026, $852036.0 in Q4 2025, and $900175.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Skye Bioscience | 10.86 Mn | 10.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 234,806.00 |
| Dec 31, 2025 | 852,036.00 |
| Sep 30, 2025 | 900,175.00 |
| Jun 30, 2025 | 1.26 Mn |
| Mar 31, 2025 | 575,382.00 |
| Dec 31, 2024 | 201,962.00 |
| Sep 30, 2024 | 2.65 Mn |
| Jun 30, 2024 | 1.10 Mn |
| Mar 31, 2024 | 1.51 Mn |
| Dec 31, 2023 | 1.12 Mn |
| Sep 30, 2023 | 867,919.00 |
| Jun 30, 2023 | 1.06 Mn |
| Mar 31, 2023 | 957,593.00 |
| Dec 31, 2022 | 780,807.00 |
| Sep 30, 2022 | 143,859.00 |
| Jun 30, 2022 | 871,428.00 |
| Mar 31, 2022 | 822,541.00 |
| Dec 31, 2021 | 56,870.00 |
| Sep 30, 2021 | 321,497.00 |
| Jun 30, 2021 | 262,836.00 |